CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Chembio Diagnostics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Chembio Diagnostics Inc
555 Wireless Blvd
Phone: (631) 924-1135p:631 924-1135 HAUPPAUGE, NY  11788-3966  United States Ticker: CEMICEMI

Business Summary
Chembio Diagnostics, Inc. is a provider of point-of-care diagnostic products for the detection and diagnosis of infectious diseases. The Company is primarily focused on expanding its product portfolio based upon its Dual Path Platform (DPP). The Company's products include rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The Company’s point-of-care infectious disease portfolio is comprised of multiple commercial products and are performed with a tiny drop of blood from the fingertip and provide results in approximately 15 minutes. The Company’s products include DPP HIV 1/2, DPP HIV-Syphilis, DPP Syphilis Screen and Confirm, DPP Zika, DPP Leishmaniasis, STAT-PAK HIV 1/2, STAT-PAK Chagas, SURE CHECK HIV 1/2 and SURE CHECK HIV 1/2 Self- Test.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/202012/31/2019YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Independent Chairman of the Board Katherine L.Davis 59 3/28/2014 5/10/2007
President, Chief Executive Officer Richard L.Eberly 3/16/2020 3/16/2020
Chief Financial Officer, Executive Vice President Neil A.Goldman 12/18/2017 12/18/2017
8 additional Officers and Directors records available in full report.

Business Names
Business Name
Brillant 3006, GmbH
CEMI
Chembio Diagnostic Systems, Inc.
5 additional Business Names available in full report.

General Information
Number of Employees: 295 (As of 12/31/2018)
Outstanding Shares: 20,161,542 (As of 7/31/2020)
Shareholders: 132
Stock Exchange: NASD
Federal Tax Id: 880425691
Fax Number: (775) 884-9383


Copyright © 2020 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, August 13, 2020